However, the vast majority of NSCLC patients receiving third-generation EGFR TKIs either do not respond to therapy or ultimately undergo disease progression, suggesting that additional resistance mechanisms are decreasing the efficacy of these inhibitors [4,43]. Here, EGFR is linked to non-small cell lung carcinoma.